KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $56.7 million.

  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) fell 1.28% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 0.60%. This contributed to the annual value of $56.7 million for FY2024, which is 4.84% up from last year.
  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) amounted to $56.7 million in FY2024, which was up 4.84% from $54.1 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $56.7 million during FY2024, and its lowest value of $34.8 million during FY2020.
  • For the 3-year period, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) averaged around $51.7 million, with its median value being $54.1 million (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 102.46% in 2020, then dropped by 6.52% in 2022.
  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $34.8 million in 2020, then skyrocketed by 36.80% to $47.6 million in 2021, then dropped by 6.52% to $44.5 million in 2022, then increased by 21.56% to $54.1 million in 2023, then rose by 4.84% to $56.7 million in 2024.